Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis
This study is currently recruiting patients.
Sponsored by: | Amgen |
---|---|
Information provided by: | Amgen |
Purpose
This study will determine whether treatment with AMG 162 can prevent lumbar spine bone loss in both early and late postmenopausal women with osteopenia, and to further test the safety and tolerability of AMG 162 in this population.
Condition | Treatment or Intervention | Phase |
---|---|---|
Postmenopausal Osteoporosis |
Drug: AMG 162 |
Phase III |
MedlinePlus related topics: Osteoporosis
Study Type: Interventional
Study Design: Prevention, Randomized, Double-Blind
Official Title: A Randomized, Double-Blind Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis
Eligibility
Ages Eligible for Study: up to 90 Years, Genders Eligible for Study: Female
Criteria
Eligibility Criteria:
Location and Contact Information
More Information
AmgenTrials clinical trials website
Center Watch Clinical Trials Listing Service
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |